
Cancer and Sexual Health

Eastern Iowa Chapter-Oncology Nurses Society March 15, 2016

Erin Sullivan, <u>erin@aftercancer.co</u> Veronika Kolder, MD, <u>veronika-kolder@uiowa.edu</u> Brad Erickson, MD, <u>brad-erickson@uiowa.edu</u>



Statistics

In 2015:

United States

• 15 million cancer survivors

<u>lowa</u>


- 140,000+ cancer survivors
- 6,00+ people will die annually
- 17,000+ newly diagnosed
- 40-100% sexual dysfunction




MY PERSONAL CANCER JOURNEY



Menopause & Sexual Health Clinic









Veronika Kolder, MD, NCMP Medical Director



Eugenia Mazur, MD, NCMP

Protocols available on request, veronika-kolder@uiowa.edu

Call to action:

the capacity to make choices about current and future ability to function sexually is essential to the health, QOL, and personhood of females with cancer

Call to action:

the capacity to make choices about current and future ability to function sexually is essential to the health, QOL, and personhood of females with cancer

CLINICAL OPINION Gynecology

ajog.org

A manifesto on the preservation of sexual function in women and girls with cancer

Stacy Tessler Lindau, MD, MAPP; Emily M. Abramsohn, MPH; Amber C. Matthews, BA



Most females with cancer have a cancer that directly affects the sexual organs


| | 2012 Prevalence | Percent of all cancers in females | |
|------------|-----------------|-----------------------------------|----|
| Breast | 2,990,813 | 40. | 9 |
| Uterus | 621,612 | 64.9 % of 8. | 5 |
| Colorectal | 589,028 | cancers in females 8. | 1 |
| Cervix | 249,512 | directly – 3. | .4 |
| Ovary | 192,446 | affect the 2. | 6 |
| Brain | 70,762 | sexual organs 1. | 0 |
| Anus | (2011) 26,298 | 0. | 4 |

2012 prevalence data from Surveillance, Epidemiology, and End Results (SEER) data, accessed 8/29/15. All sites, female, 2012 = 7,311,722

Cancer and cancer treatment can impair female sexuality


| Cancer Site | Most Common Sexual Problems | Prevalence | |
|--|--------------------------------|------------|---|
| Breast | | | |
| | Overall | 30-100% | |
| | Desire | 23-64% | |
| | Arousal/lubrication | 20-48% | Stan Bobe |
| | Orgasm | 16-36% | et al. I er & Va |
| | Pain/dyspareunia | 35-38% | Hemat Irela. J |
| | Body image concerns | 30-67% | tol On Clin C |
| | Poor nipple sensation | >90% | col Clii Onc 20 |
| Gynecologic (ovarian & cervical only) | | | Stan et al. Hematol Oncol Clin North Am 2013;27(4):805 Bober & Varela. J Clin Onc 2012;30:3712-9 |
| | Overall | ≤80% | .m 201 12-9 |
| Colorectal | | | 13;27(|
| | Overall | 6-60% | 4):805 |

The web of female sexual dysfunction



Adapted from Phillips. Am Fam Physician 2000;62(1):127-36

Women and girls with cancer value their sexuality













Boehmer et a. J Sex Research 2014;51(6):681-9 Lindau et al. DOI: 10.1016/j.ajog.2015.03.039

Young Breast Cancer Survivors: David Jay, The SCAR Project, 2005

Loss of sexual function has negative health consequences for females and their partners

| | % Female cancer | % Female controls | RR (95% CI) | % Male Cancer | % Male Control | RR (95% CI) |
|------------------------|--------------------|----------------------|----------------------|------------------|-------------------|---------------------|
| Ever married | 79 | 77 | 1.03 (0.97- 1.09) | 76 | 70 | 1.08 (0.94-1.25) |
| Currently married | 58 | 65 | 0.91 (0.83- 0.99) | 62 | 61 | 1.03 (0.87-1.22) |
| Divorced/s eparated | 21 | 11 | 1.83 (1.49- 2.25) | 13 | 8.2 | 1.57 (0.69-3.56) |

2009 Behavioral Risk Factor Surveillance System database. Young female survivors age 20-39 are less likely to be married and more likely to be divorced or separated compared to controls without cancer. In male young adult cancer survivors, percent currently married and percent divorced or separated was not significantly different from male controls without cancer. N=1198 survivors (ave time since dx 7.4 years), 67063 controls. Analysis adjusted for age, race, highest attained education. Bold values are significant at $\alpha = 0.05$.

Kirchhoff et al. J Cancer Surv 2012;6(4):441-450 Karraker & Latham. J Health Soc Behav 2015;56(3):420-35

Loss of sexual function has negative health consequences for females and their partners

| | % Female cancer | % Female controls | RR (95% CI) | % Male Cancer | % Male Control | RR (95% CI) |
|------------------------|--------------------|----------------------|----------------------|------------------|-------------------|---------------------|
| Ever married | 79 | 77 | 1.03 (0.97- 1.09) | 76 | 70 | 1.08 (0.94-1.25) |
| Currently married | 58 | 65 | 0.91 (0.83- 0.99) | 62 | 61 | 1.03 (0.87-1.22) |
| Divorced/s eparated | 21 | 11 | 1.83 (1.49- 2.25) | 13 | 8.2 | 1.57 (0.69-3.56) |

2009 Behavioral Risk Factor Surveillance System database. Young female survivors age 20-39 are less likely to be married and more likely to be divorced or separated compared to controls without cancer. In male young adult cancer survivors, percent currently married and percent divorced or separated was not significantly different from male controls without cancer. N=1198 survivors (ave time since dx 7.4 years), 67063 controls. Analysis adjusted for age, race, highest attained education. Bold values are significant at $\alpha = 0.05$.

Kirchhoff et al. J Cancer Surv 2012;6(4):441-450 Karraker & Latham. J Health Soc Behav 2015;56(3):420-35

Patients want to preserve their sexuality but rarely ask for help

Providers



Patients

Tools for assessing female sexual function are available



Survivorship: Sexual Dysfunction (Female), Version 1.2013


Crystal S. Denlinger, Robert W. Carlson, Madhuri Are, K. Scott Baker, Elizabeth Davis, Stephen B. Edge, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Elizabeth Kvale, Terry S. Langbaum, Jennifer A. Ligibel, Mary S. McCabe, Kevin T. McVary, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Tracey O'Connor, Electra D. Paskett, Muhammad Raza, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole McMillian and Deborah Freedman-Cass

J Natl Compr Canc Netw 2014;12:184-192

DIAGNOSTIC EVALUATION


Ask about sexual function at regular intervals

- Use the Brief Sexual Symptom Checklist as a primary screening tool^a
- Review present and past level of sexual activity and discuss the potential impact of therapy. Discuss any sexual concerns and how cancer treatment has affected sexual functioning and intimacy
- Discuss treatment-associated infertility if indicated, with appropriate referrals



NCCN Guideline,


Denlinger et al. JNCCN 2014;12(2):184-92



Brief Sexual Symptom Checklist

BRIEF SEXUAL SYMPTOM CHECKLIST FOR WOMEN¹

| Please answer the following questions about your overall sexual function 1. Are you satisfied with your sexual function? YesNo If no, please continue. |
|--|
| 2. How long have you been dissatisfied with your sexual function? |
| 3a. The problem(s) with your sexual function is: (mark one or more) 1 Problem with little or no interest in sex 2 Problem with decreased genital sensation (feeling) 3 Problem with decreased vaginal lubrication (dryness) 4 Problem reaching orgasm 5 Problem with pain during sex 6 Other: |
| 3b. Which problem is most bothersome? (circle) 1 2 3 4 5 6 |
| 4. Would you like to talk about it with your doctor? YesNo |





NCCN Guidelines Version 1.2015 Anxiety and Depression


http://cache1.medsci.cn/webeditor/uploadfile/201503/20150325140423575.pdf

SANXDE-1 ANXIETY AND DEPRESSION SCREENING

- Do you feel nervous, or do you worry?
- Do you worry that your cancer will recur?
- Do you have trouble controlling your worry?
- Do you have trouble sleeping? (eg, staying asleep, falling asleep, too much sleep)b
- Do you have difficulty concentrating?
- Do you have less interest or enjoyment in activities?
- Do you feel sad or depressed?
- Are you having difficulty performing daily activities because of these (above mentioned) feelings or problems?

NCCN National Comprehensive Cancer Network*

Distress Management



ADDITIONAL EVALUATION

TREATMENT

٥

٥


counseling

≻

→

POSTTREATMENT EVALUATION

- Evaluate for the following categories of female sexual dysfunctions:
 - ► Sexual desire disorder
 - Sexual arousal disorder
 - Female orgasm disorder
 - Sexual pain disorder
- Discuss concerns related to specific cancer therapies
- If treatment-related menopause, assess symptoms and effects on sexual functioning
- · Perform physical and gynecologic exam to note points of tenderness, vaginal atrophy, and anatomic changes associated with cancer surgeries and treatments
- For more in-depth evaluation of sexual dysfunction, consider the Female Sexual Function Index (FSFI)^b



visits/post therapy Repeat evaluation and treatment options, with appropriate referrals for psychotherapy, sexual counseling as indicated

Reevaluate at

subsequent

NCCN Guideline,

Denlinger et al. JNCCN 2014;12(2):184-92

ADDITIONAL EVALUATION

TREATMENT

٥


٥

≻

→


POSTTREATMENT EVALUATION

- Evaluate for the following categories of female sexual dysfunctions:
- ► Sexual desire disorder
- Sexual arousal disorder
- Female orgasm disorder
- Sexual pain disorder
- Discuss concerns related to specific cancer therapies
- If treatment-related menopause, assess symptoms and effects on sexual functioning
- · Perform physical and gynecologic exam to note points of tenderness, vaginal atrophy, and anatomic changes associated with cancer surgeries and treatments
- For more in-depth evaluation of sexual dysfunction,
 - consider the Female Sexual Function Index (FSFI)^b



counseling

FSFI available at http://www.fsfiguestionnaire.com/



indicated

NCCN Guideline, Denlinger et al. JNCCN 2014;12(2):184-92


٥

٥

►

POSTTREATMENT EVALUATION

- Evaluate for the following categories of female sexual dysfunctions:
 - ► Sexual desire disorder
 - Sexual arousal disorder
 - Female orgasm disorder
 - ► Sexual pain disorder
- Discuss concerns related to specific cancer therapies
- If treatment-related menopause, assess symptoms and effects on sexual functioning
- Perform physical and gynecologic exam to note points of tenderness, vaginal atrophy, and anatomic changes associated with cancer surgeries and treatments
- For more in-depth evaluation of sexual dysfunction, consider the Female Sexual Function Index (FSFI)^b



NCCN Guideline, Denlinger et al. JNCCN 2014;12(2):184-92

referrals for

٥


٥

counseling

►

POSTTREATMENT EVALUATION

- Evaluate for the following categories of female sexual dysfunctions:
 - ► Sexual desire disorder
 - Sexual arousal disorder
 - Female orgasm disorder
 - ► Sexual pain disorder
- Discuss concerns related to specific cancer therapies
- If treatment-related menopause, assess symptoms and effects on sexual functioning
- Perform physical and gynecologic exam to note points of tenderness, vaginal atrophy, and anatomic changes associated with cancer surgeries and treatments
- For more in-depth evaluation of sexual dysfunction, consider the Female Sexual Function Index (FSFI)^b



NCCN Guideline,

Denlinger et al. JNCCN 2014;12(2):184-92

٥


٥

counseling

►

POSTTREATMENT EVALUATION


- Evaluate for the following categories of female sexual dysfunctions:
 - ► Sexual desire disorder
 - Sexual arousal disorder
 - Female orgasm disorder
 - Sexual pain disorder
- Discuss concerns related to specific cancer therapies
- If treatment-related menopause, assess symptoms and effects on sexual functioning
- Perform physical and gynecologic exam to note points of tenderness, vaginal atrophy, and anatomic changes associated with cancer surgeries and treatments
- For more in-depth evaluation of sexual dysfunction, consider the Female Sexual Function Index (FSFI)^b



NCCN Guideline, Denlinger et al. JNCCN 2014;12(2):184-92

POSTTREATMENT EVALUATION


- Evaluate for the following categories of female sexual dysfunctions:
 - Sexual desire disorder
 - Sexual arousal disorder
 - ► Female orgasm disorder
 - Sexual pain disorder
- Discuss concerns related to specific cancer therapies
- If treatment-related menopause, assess symptoms and effects on sexual functioning
- Perform physical and gynecologic exam to note points of tenderness, vaginal atrophy, and anatomic changes associated with cancer surgeries and treatments
- For more in-depth evaluation of sexual dysfunction, consider the Female Sexual Function Index (FSFI)^b



NCCN Guideline, Denlinger et al. JNCCN 2014;12(2):184-92

POSTTREATMENT EVALUATION

- Evaluate for the following categories of female sexual dysfunctions:
 - Sexual desire disorder
 - Sexual arousal disorder
 - ► Female orgasm disorder
 - ► Sexual pain disorder
- Discuss concerns related to specific cancer therapies
- If treatment-related menopause, assess symptoms and effects on sexual functioning
- Perform physical and gynecologic exam to note points of tenderness, vaginal atrophy, and anatomic changes associated with cancer surgeries and treatments
- For more in-depth evaluation of sexual dysfunction, consider the Female Sexual Function Index (FSFI)^b




NCCN Guideline,

ADDITIONAL EVALUATION

treatments

TREATMENT

POSTTREATMENT EVALUATION



NCCN Guideline, Denlinger et al. JNCCN 2014;12(2):184-92



• Routinely ask about patient sexual function



- Routinely ask about patient sexual function
- Provide anticipatory guidance



- Routinely ask about patient sexual function
- Provide anticipatory guidance
- Normalize the patient's concerns and arrange a time to focus specifically on them



- Routinely ask about patient sexual function
- Provide anticipatory guidance
- Normalize the patient's concerns and arrange a time to focus specifically on them
- Provide resources



- Routinely ask about patient sexual function
- Provide anticipatory guidance
- Normalize the patient's concerns and arrange a time to focus specifically on them
- Provide resources
- Develop expertise to fill this need for care in your community



Cancer Survivorship

• Bradley A. Erickson, MD

Pre-operative discussion

- <u>Any</u> oncologic intervention in the pelvis can lead to both short-term and long-term post-treatment sexual and urological side effects.
 - Radiation delayed
 - Surgery immediate
- Pre-intervention discussion generally involves discussion of cancer treatment.
- Pre-intervention sexual/urologic sequelae are rarely discussed.

Typical Prostate Cancer Patient

58 M, diagnosed with prostate cancer after undergoing prostate biopsy for elevated PSA (6.5). Biopsy showed Gleason 3+4 Prostate cancer in 3 of 12 cores. Decision to undergo robotic assisted laparoscopic prostatectomy



Prostate Cancer Risk

| <u>earn more</u> about your results below. Current Model | | | Historical Model | | |
|--|---------|------------|---|---------|---|
| Extent of Disease Probability | | | Extent of Disease Probability | | |
| Indolent Cancer | | <u>N/A</u> | Indolent Cancer | | |
| Organ Confined Disease | | 74% | Organ Confined Disease | | |
| Extracapsular Extension | | 17% | Extracapsular Extension | | Γ |
| Seminal Vesicle Invasion | | 4% | Seminal Vesicle Invasion | | Γ |
| Lymph Node Involvement | | 2.6% | Lymph Node Involvement | | |
| Primary Treatment C | Outcome | | Primary Treatment C | utcome | |
| Progression Free Probability after Radical Prostatectomy | 5 Year | 93% | Progression Free Probability after Radical Prostatectomy | 5 Year | |
| | 10 Year | 90% | | 10 Year | ſ |
| <u>Probability of</u> <u>Cancer-Specific</u> <u>Survival</u> | 10 Year | 99% | | | - |
| | 15 Year | 99% | | | |


Age: 58 PSA: 6.5 Gleason 3+4 3/12 cores positive

Memorial Sloan Kettering Treatment Nomogram: http://nomograms.mskcc.org/Prostate/PreTreatment.aspx



Erectile Dysfunction and Incontinence Risk?

- Historical Rates:
 - Continence = 95%
 - Potency = 70%
- Reality \rightarrow



Eur J Surg Onc. 2014 Jul 18



Prostate Cancer Treatment

- <u>All men undergoing radical</u> retropubic prostatectomy will experience <u>SOME</u> postoperative erectile dysfunction and stress incontinence
- Recovery can take <u>YEARS</u>
- Many men are misinformed or misunderstand





Misinformed Patients

Patient Preoperative Expectations of Urinary, Bowel, Hormonal and Sexual Functioning Do Not Match Actual Outcomes 1 Year After Radical Prostatectomy

Daniela Wittmann,* Chang He, Michael Coelho, Brent Hollenbeck, James E. Montie and David P. Wood, Jr.†

From the Department of Urology (DW, CH, MC, BH, JEM, DPW) and Department of Social Work-Center for Sexual Health (DW), University of Michigan, Ann Arbor, Michigan

•12% of patients expected BETTER urinary control•17% of patients expected IMPROVED erections

Surgical Treatment

- Discussion of "sparing" or "not-sparing" nerves can often lead to increased expectations of post-operative recovery.
- While "nerve-sparing" approaches increase chances of recovery, it should never be "expected".





Post-Operative Rehabilitation

Post-op Rehabilitation should begin before surgery.

Good to understand keys to recovering urinary control and erections post-operatively: •Urinary control - Kegel Exercises

•Erections - Kegel Exercises, +/- PDE-5 (e.g. Viagra) and/or Vacuum erection devices



Rehab after Knee Replacement



Penile Rehab after Prostatectomy

WA



Urinary Sphincter Rehab after Prostatectomy

Post-Operative Regret

- Regret is common (>20% of men)
- Most influenced by postoperative erectile dysfunction and incontinence
- More common in men undergoing robotic surgery
 - Expectations are higher?
 - Marketing?






Health Related Quality of Life – Post-Treatment



HDXRT~ I-125^ RP

Bowel Function

Sexual Function





Multidisciplinary Approach to Survivorship

The effects of multidisciplinary rehabilitation: RePCa—a randomised study among primary prostate cancer patients

K B Dieperink^{*,1}, C Johansen², S Hansen¹, L Wagner³, K K Andersen⁴, L R Minet⁵ and O Hansen¹

Conclusion: Multidisciplinary rehabilitation in irradiated PCa patients improved urinary and hormonal symptoms, and SF-12 physical QoL.





What can nursing do? – Call to action...

- Be the patient advocate
- Provide information
- Pre-operative counseling and early referrals
 - Post-operative/chemo sexual function is not a "complication" its an expectation



What about the Partner?

Survivorship After Prostate Cancer Treatment: Spouses' Quality of Life at 36 Months

Janet Harden, PhD, RN, Martin G. Sanda, MD, John Thomas Wei, MD, Hossein N. Yarandi, PhD, Larry Hembroff, PhD, Jill Hardy, BA, and Laurel Northouse, PhD, RN

Conclusions: Spouses continued to experience negative appraisal of caregiving, which affected QOL 36 months after their husbands' treatment for prostate cancer. Additional studies related to factors that influence spouse QOL during survivorship will help guide clinical practice.

Knowledge Translation: Spouses who experienced more bother related to urinary, sexual, and hormonal function experience more stress and worse QOL at 36 months post-treatment. Spouse appraisal can have a significant effect on QOL. Offering counseling to couples following treatment for prostate cancer many improve QOL by helping couples manage relationship intimacy.



Conclusions

- Prostate Cancer treatment is very successful at managing prostate cancer with high cancer specific survival
- With prolonged survival after CAP treatment, survivorship issues specific to CAP (e.g. ED and incontinence) become more important
- Perioperative counseling focuses on the cancer
- Rehabilitation can help, but ED and incontinence are COMMON and UNDERREPORTED/APPRECIATED
- A team approach that begins pre-op is ideal
- It STARTS WITH NURSES!!!!!



Points To Remember

- Sexual health issues are common as a result of many cancer treatments
- Patients want medical teams to address this topic, set expectations and provide resources
- Treatment can impact the outcome if addressed early
- Sexual health issues=Medical issues=Quality of life issues
- Loss of Sexual functioning has consequences on intimate relationships
- There are resources to address issues for providers and patients (www.aftercancer.co)
- Patients need your help, guidance and support

Addressing Sexual Health Issues with Patients

